Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals

Figures & data

Table 1 Summary of clinical trials investigating efficacy of telmisartan

Names of the clinical trials or the authors	Study subjects	Main results
MICADO study^Citation12	Hypertensive patients	Greater sustained BP reduction than valsartan
Miura et al^Citation20	Hypertensive patients with type 2 diabetes	Greater improvement of insulin resistance, elevation of adiponectin, and reduction in CRP than valsartan or candesartan
ONTARGET study^Citation27	Patients at high-risk	Equivalent efficacy in preventing cardiovascular events as ramipril
TRANSCEND study^Citation28	Patients at high-risk who are intolerant to ACE inhibitors	Equivalent efficacy in preventing cardiovascular events as placebo
		Tolerance of telmisartan in patients intolerant to ACE inhibitors

Abbreviations: BP, blood pressure; CRP, C-reactive protein; ACE, angiotensin-converting enzyme.

Figure 1 Ideal indication of telmisartan.

Abbreviation: PPARγ, peroxisome proliferator activated receptor gamma.

Table 2 Summary of clinical trials investigating efficacy of telmisartan/HCTZ tablets

Names of the clinical trial or the authors	Study subjects	Main results
Higaki^Citation32	Hypertensive patients	Greater reduction of BP than telmisartan alone
Lacourcière et al^Citation33	Hypertensive patients	Greater reduction of BP than telmisartan alone
Neutel et al^Citation38	Hypertensive patients	Greater reduction of BP than losartan/HCTZ tablets
SMOOTH study^Citation39	Overweight/obese hypertensive patients	Greater reduction of BP than valsartan/HCTZ tablets

Abbreviation: BP, blood pressure; HCTZ, hydrochlorothiazide.

LacourcièreYKrzesinskiJMWhiteWBDavidaiGSchumacherHSustained antihypertensive activity of telmisartan compared with valsartanBlood Press Monit2004920321015311147

 PubMed Web of Science ®Google Scholar

MiuraYYamamotoNTsunekawaSReplacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetesDiabetes Care20052875775815735228

 PubMed Web of Science ®Google Scholar

The ONTARGET InvestigatorsTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med20083581547155918378520

 PubMed Web of Science ®Google Scholar

The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) InvestigatorsEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200937211741183

 Web of Science ®Google Scholar

HigakiJThe examination of telmisartan 40 mg/hydrochlorothiazide for patients with essential hypertensionJ New Remedies and Clinic200857308325

 Google Scholar

LacourcièreYTytusRO’KeefeDLenisJOrchardRMartinKEfficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapyJ Hum Hypertens20011576377011687919

 PubMed Web of Science ®Google Scholar

NeutelJMLittlejohnTWChrysantSGSinghATelmisartan Study GroupTelmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertensionHypertens Res20052855556316335883

 PubMed Web of Science ®Google Scholar

SharmaAMDavidsonJKovalSLacourcièreYTelmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: The SMOOTH studyCardiovasc Diabetol200762817910747

 PubMed Web of Science ®Google Scholar